AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors
Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization
Prof. Bütler is a leading Swiss economist and former Vice President of the independent Swiss Covid-19 Science Taskforce
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.